Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended April 30, 2000 (Fiscal Year 2000)
Business Overview: Cooper develops, manufactures, and markets healthcare products through two primary segments: CooperVision (CVI), specializing in contact lenses, and CooperSurgical (CSI), focusing on women's healthcare diagnostic and surgical products.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Apr 30, 2000 |
6 Months Ended Apr 30, 2000 |
6 Months Ended Apr 30, 1999 |
|---|---|---|---|
| Net Sales | $50,769 | $91,173 | $76,702 |
| Gross Profit | $32,484 | $59,116 | $48,112 |
| Gross Margin | 64% | 65% | 63% |
| Income from Operations | $11,377 | $19,617 | $15,526 |
| Net Income | $6,763 | $11,158 | $11,034 |
| Diluted EPS (Continuing Ops) | $0.47 | $0.80 | $0.55 |
| Cash from Operations | N/A | $15,915 | $5,793 |
| Cash & Equivalents (End Period) | $4,747 | $4,747 | $5,441 |
| Total Debt | $54,504 | $54,504 | $59,372 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 22% ($9.0M) for the quarter and 19% ($14.5M) for the six-month period compared to the prior year.
- Segment Performance:
- CooperVision (CVI): Revenue grew 10% (quarter) and 12% (six months), driven by 21% growth in U.S. core product sales, specifically disposable-planned replacement (DPR) toric and spherical lenses.
- CooperSurgical (CSI): Revenue surged 78% (quarter) and 47% (six months), primarily due to the acquisitions of BEI Medical Systems products and the Leisegang Business.
- Profitability: Income from operations rose 18% for the quarter and 26% for the six-month period. Gross margin improved to 65% for the six-month period, aided by cost reductions at CVI, though CSI margins declined slightly due to the lower-margin acquired products.
- Debt Reduction: Total debt decreased from $59.4M to $54.5M. The company repaid a $17.4M Midland Bank loan and replaced it with lower-cost debt under the KeyBank line of credit, reducing interest expense by 27% year-over-year.
- Accounting Change: A one-time after-tax charge of $432,000 was recorded in the first quarter due to the adoption of SOP 98-5 regarding start-up activities.
Outlook, Risks, and Management Commentary
- Acquisitions: Completed two significant acquisitions in the period: BEI Medical Systems products ($10.3M cash) and the Leisegang Business (~$10M cash). These are expected to drive future growth in the women's healthcare segment.
- Liquidity: Management expects cash on hand ($4.7M) plus operating cash flow to fund operations, capital expenditures, dividends, and smaller acquisitions. Approximately $26.8M remains available under the KeyBank line of credit.
- Tax Strategy: Implemented a global tax plan to utilize net operating losses (NOLs), projecting an effective tax rate reduction to approximately 30% over the next six years.
- Risks:
- Foreign Exchange: Exposure to Pound Sterling debt and foreign operations; hedging strategies are in place.
- Environmental: Groundwater contamination (TCA) at a CVI site; remediation costs are accrued at $400,000 and are not expected to be material.
- Integration: Risks associated with integrating recent acquisitions and potential dilution from future stock issuances.
Investor Verification Checklist
- Acquisition Synergies: Verify if the revenue growth in CSI is sustainable post-acquisition and if margin compression stabilizes as projected (53% target).
- Cash Position: Monitor the low cash balance ($4.7M) relative to the $23.5M spent on acquisitions and $6.2M in capital expenditures; confirm reliance on the KeyBank line of credit.
- CVI Product Mix: Confirm continued market share gains in the high-margin DPR toric and spherical lens categories.
- Debt Covenants: Review the terms of the KeyBank line of credit to ensure compliance with covenants given the recent refinancing.
- Environmental Liability: Track the progress of the CVI site remediation to ensure costs remain within the accrued $400,000 estimate.